血糖控制和管理的开发:糖原储存疾病
Xin Qi1, Minh N Ta1, Richard F Tester1
1Glycologic Limited, Reading, United Kingdom.
Journal of medicinal food
|November 15, 2023
概括
味的缓慢释放能量饼干 (GLY-HYP) 在患有 I 型和 IV 型葡萄糖储存疾病 (GSD) 的患者中显示出稳定的血糖反应. 这些发现表明,GLY-HYP饼干可能是GSD患者有益的饮食选择.
科学领域:
- 代谢障碍 代谢障碍 代谢障碍
- 营养科学 营养科学
- 临床营养学 临床营养学
背景情况:
- 糖原储存疾病 (GSDs) 是一组影响葡萄糖代谢的遗传代谢障碍.
- 控制血糖水平对于患有GSD的人来说至关重要,以防止低血糖和其他并发症.
- 以前的研究表明,GLY-HYP饼干在健康个体中提供缓慢,持续的葡萄糖释放.
研究的目的:
- 为了评估血糖对GLY-HYP爆破剂的反应,在GSD类型I和IV的患者中.
- 为了确定GLY-HYP饼干作为GSD患者的饮食成分的适用性.
主要方法:
- 一项临床研究涉及成年志愿者被诊断患有GSD类型I和IV.
- 参与者食用了GLY-HYP饼干,他们的血糖水平在4小时内被监测.
- 分析血糖度趋势,包括峰值水平和基线以上的持续时间.
主要成果:
- 在GSD I型患者 (53-70岁) 中,60分钟后血糖达到9.5mmol/L的峰值,在210分钟内保持在基线以上,并在4小时内保持在5mmol/L以上.
- 在GSD IV型患者 (55-72岁) 中,血糖在45分钟后达到10.2 mmol/L的峰值,在150分钟内保持在基线以上,并在4小时内保持在5 mmol/L以上.
- 两组GSD都表现出相对平坦的血糖反应,类似于健康个体.
结论:
- 在GSD类型I和IV的个体中,GLY-HYP饼干显示出有利的,持续的血糖反应.
- 这些饼干代表了一种潜在的有价值的营养选择,用于管理各种年龄组GSD患者的饮食需求.
- 进一步的研究可能会探索GLY-HYP破解剂在GSD管理中的长期影响和更广泛的适用性.
更多相关视频
08:13Study of In Vivo Glucose Metabolism in High-fat Diet-fed Mice Using Oral Glucose Tolerance Test OGTT and Insulin Tolerance Test ITT
Published on: January 7, 2018
68.6K
06:59Characterization of Metabolic Status in Nonhuman Primates with the Intravenous Glucose Tolerance Test
Published on: November 13, 2016
11.0K
相关概念视频
Hypoglycemia and Glucagon
274
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
274
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
183
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
183
Overview of Carbohydrate Metabolism
1.1K
Carbohydrate metabolism is a fundamental biochemical process that ensures a constant supply of energy to living cells. The most important carbohydrate is glucose, which can be broken down via glycolysis to enter into the Krebs cycle and eventually lead to the production of ATP through oxidative phosphorylation.
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
Glucose transport into cells is facilitated by a family of transport proteins called GLUT (Glucose Transporters). GLUT4 is the primary glucose transporter for insulin-stimulated glucose...
1.1K
Glucose Transporters
22.8K
Glucose transporters facilitate the transport of glucose across the cell membrane. In addition to glucose, some glucose transporters can also aid the movement of other hexoses such as fructose, mannose, and galactose.
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
Facilitated diffusion-glucose transporters (GLUTs) are encoded by the solute-linked carrier (SLC) family 2, subfamily A gene family, or SLC2A. The 14 GLUT protein members are distributed into three classes:
22.8K
Glucagon-like Receptor Agonists
332
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
332
Glucose Absorption Into the Small Intestine
31.7K
Complex carbohydrates consumed cannot be absorbed into the small intestine in their original form. First, they must be hydrolyzed to a monosaccharide form such as glucose or galactose. These monosaccharides are then transported across the intestinal membrane and into the blood via transcellular transport. The intestinal epithelial cells allow the movement of these monosaccharides with a defined 'entry' through membrane transporter proteins present on their apical membrane and...
31.7K
